Company Overview
CommBio Therapeutics is dedicated to developing a new class of medicine – genetically engineered bacteria, for a broad range of complex diseases. This novel modality, termed bacterial vector gene therapy or recombinant live biotherapeutics, leverages the rapid advances in the field of intestine biology and powered by the development of synthetic biology tools over the last two decades.
Scientific research continues to provide evidence that many diseases’ are modulated by signals/targets from within the gut. Our approach at CommBio is to integrate disease-curing-genes into the chromosome of gut bacteria using synthetic biology tools, such that these bacteria can accurately deliver disease modulating signals as they pass through the human gut. We believe that this modality has great potential to become a breakthrough therapy for specific types of diseases. As of now, programs in our pipeline target a broad range of indications including metabolic, autoimmune, neurodegenerative diseases, and cancer. Along-side our drug pipeline, we have also designed bacteria based products that address daily health needs such as alcohol metabolism that prevent hangovers as well as associated toxicities, and products that assist weight loss, which we plan to develop as consumer products.
CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists, and experts in IP, finance and operations. 80% of our FTE work in R&D function. About third of our employees hold PhD degree, and about fourth have studied or worked abroad (returnees).
To pioneer and become the leading company in the application of bacterial vector gene therapy to meet the medical needs of patients in the Chinese and global markets.
To bring high quality, first-in-class and best-in-class therapeutics to patients in China and worldwide that are safe, effective and affordable by a restless and relentless dedication to innovation.
Science, Innovation, Dedication
CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists and experts in IP, finance and operations.
Co-Founder & Chief Executive Officer
Co-Founder & Chief Operations Officer
CommBio was founded in Zhangjiang Pharma Valley, Shanghai, China in 2019 by two experienced scientists from The Novartis Institutes for BioMedical Research (NIBR). Our current team include pharmaceutical industry veterans, world-renowned scientists and experts in IP, finance and operations.
Scientific Advisory Board, Chair
Scientific Advisor
Scientific Advisor
Scientific Advisor
CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1